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Summary
Although there are differences in the pharmacokinetic profiles of oral and non-oral routes of administration the cli-
nical relevance of these differences remains to be determined. Likewise, there are differences in the metabolic and
haemostatic effects of different routes of administration of oestrogen but these may have clinical relevance. For
some parameters, such as lipids and lipoproteins, glucose and insulin metabolism, there are greater benefits from
oral administration; for others, particularly haemostatic changes and effects on CRP, there are advantages from
transdermal administration. For the potential benefits of HRT on CHD, these differences probably have less impact
than the effect of the dose of hormones used and the lowest effective should be prescribed.
Irrespective of dose, certain small sub-groups of patients should be specifically treated with an oral regimen eg those
with lipid and lipoprotein abnormalities and impaired glucose tolerance whereas others should be treated with a
transdermal regimen eg those with a personal or relevant family history of venous thrombosis. However, the vast
majority of patients possess none of these risk factors and for them it will come down to personal preference. The
availability of different combinations and doses of hormones, as well as different routes of administration, allows
HRT to be tailored to the individual and there are few women for whom a  suitable form of HRT cannot be found.
Although data are lacking we believe it unwise to believe that fully transdermal combination therapy will not impact
on risk of incident breast cancer. Based on current evidence transdermal HRT may also cause more irregular and
breakthrough bleeding with sequential and continuous therapies than oral counterparts .
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Streszczenie
Zmiany w efekcie metabolicznym i hemostatycznym w wyniku ró˝nej drogi podania estrogenów mogà mieç znacze-
nie kliniczne. Profil farmakokinetyczny po podaniu doustnym mo˝e byç odmienny ni˝ po podaniu leku innà drogà,
nale˝y jednak okreÊliç znaczenie kliniczne tej ró˝nicy. 
Parametry biochemiczne, takie jak st´˝enie lipidów i lipoprotein, glukozy oraz metabolizm insuliny, wykazujà
korzystniejszy profil po podaniu doustnym; lecz dla innych parametrów, szczególnie w zakresie hemostazy i wp∏ywu
na CRP, wi´ksze korzyÊci istniejà z podania przezskórnego.
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Introduction
The development in the late 1970’s / early 1980’s of non-
oral forms of hormone replacement therapy (HRT), such as
percutaneous gels and transdermal patches, soon led to valid
discussion as to whether these had advantages over oral HRT.
Unfortunately, competing commercial interests rapidly
reduced this healthy scientific debate to a controversy, and
with selective use of the literature oral HRT could be made to
appear to have more favourable effects than non-oral HRT, or
vice-versa. Not surprisingly, the average clinician became
completely confused.
Periodically over the last 25 years this controversy has
resurfaced. It has recently reappeared following the publica-
tion of the Women’s Health Initiative (WHI) results with oral
therapy. These were not as favourable as expected. Therefore,
the manufacturers of the non-oral treatments have attempted
to distance their products from the WHI results on the basis
that non-oral HRT is somehow different and safer than oral
treatment. But is this justified?
We have more then 60 years of combined research experi-
ence with HRT and have worked on the development of oral,
transdermal and percutaneous treatments from the middle
1970s. This manuscript expresses our views on the current sta-
tus of the debate on the safety and efficacy of oral versus non-
oral HRT.
Physiology and Pharmacology
The demonstration that oestradiol could be absorbed
through the skin and into plasma in amounts sufficient to alle-
viate oestrogen deficiency symptoms from percutaneous gels
(Whitehead et al., 1979) and transdermal patches (Schenkel et
al., 1982) led to a detailed pharmacokinetic and pharmacody-
namic evaluation of these different routes of administration.
Later research included buccal, sub-lingual and intranasal
administration.There is a very comprehensive recent review of
this topic [1].
Because only percutaneous and transdermal routes have
gained widespread patient acceptance, only these will be con-
sidered here. Compared to oral HRT, transdermal oestradiol
was shown to produce a more physiological
oestradiol/oestrone ratio and lower doses could be adminis-
tered because of the avoidance of the “first-pass” hepatic
metabolism. However, even to this day, we do not know
whether the differences in the oestradiol/oestrone ratio
between non-oral and oral forms of HRT, and the higher plas-
ma oestrone sulphate and sex hormone binding globulin
(SHBG) levels achieved with oral therapy have meaningful
clinical implications with regard to beneficial oestrogenic
effects and side-effects.
It should be remembered that the liver metabolises more
than 98% of circulating oestradiol and that the entire blood
volume, 5 litres, passes through the liver every minute. Thus,
any  form of HRT must have a hepatic impact if given in ther-
apeutic doses. If the same type of oestrogen is given orally and
non-orally in comparable doses, then any difference in hepat-
ic metabolism eg lipid or coagulation status, between the
routes of administration will be due to the “first pass” effect
seen only with oral administration. 
The principal issue regarding oral and non-oral HRT is
the possible different effects on arterial and venous disease
risk. These will now be considered in detail.
HRT effects on metabolic risk factors for
coronary heart disease (CHD)
There are many metabolic changes that accompany the use
of HRT, and these vary with the doses of steroids used, the
types of preparations (both oestrogens and progestogens), and
the route of administration.
Oestrogen lowers total cholesterol, regardless of type of
steroid or route of administration, and this effect is main-
tained in the long term whilst on treatment [2]. This reduction
in cholesterol results primarily from a decrease in the poten-
tially atherogenic low density lipoprotein (LDL) cholesterol
concentrations due to an up-regulation of apoB100 receptors.
Oral oestrogen is more effective than transdermal oestrogen in
this respect [3]. 
Oral HRT may increase the proportion of small dense
LDL particles [4], but it also increases their clearance from the
circulation [5]. 
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Korzystny wp∏yw hormonalnej terapii zast´pczej na CHD w mniejszym stopniu zale˝y od drogi podania leku, nato-
miast du˝e znaczenie ma dawka hormonu, który powinien byç przepisany w najmniejszej skutecznej iloÊci.
Niezale˝nie od dawki, pewna, niewielka grupa pacjentek powinna byç leczona drogà doustnà. Sà to kobiety z za-
burzeniami lipidowymi i lipoproteinowymi oraz z nieprawid∏owà tolerancjà glukozy. Terapi´ przezskórnà powinno
si´ natomiast zalecaç kobiet z rodzinnym wyst´powaniem lub z przebytà zakrzepicà ˝ylnà. Jakkolwiek wi´kszoÊç
pacjentek nie posiada czynników ryzyka i dlatego wybór drogi podania leku zale˝y od ich osobistych preferencji. 
Dost´pnoÊç ró˝nych kombinacji i dawek hormonów, a tak˝e ró˝ne drogi podania leku, pozwalajà na indywidualne
dostosowanie hormonalnej terapii zast´pczej, tak i˝ niewiele jest kobiet, dla których nie mo˝na znaleêç odpowied-
niego preparatu.
Chocia˝ brakuje jeszcze danych, uwa˝amy ˝e nie ma wystarczajàcych przes∏anek, aby stwierdziç, ˝e przezskórna
z∏o˝ona terapia nie ma wp∏ywu na ryzyko raka piersi. W oparciu o dotychczasowe dowody naukowe, przezskórna
hormonalna terapia zast´pcza, zarówno sekwencyjna jak i ciàg∏a, mo˝e cz´Êciej powodowaç nieprawid∏owe
krwawienia ni˝ jej doustne odpowiedniki.    
S∏owa kluczowe: menopauza / menopauza – powik∏ania / menopauza – wp∏yw Êrodków
chemicznych / terapia hormonalna zast´pcza / terapia hormonalna zast´pcza –
przeciwwskazania / terapia hormonalna zast´pcza – stosowanie leczenia / 
/ terapia hormonalna zast´pcza – dzia∏anie szkodliwe /
Thus, their shortened residence time in the circulation
should reduce the likelihood of their retention in the arterial
wall. Transdermal oestradiol does not decrease LDL particle
size [6], but it is not known if it improves LDL particle clear-
ance. Small dense LDL particles may be more susceptible to
oxidative damage, leading to foam cell production and the
generation of atheroma, but somewhat contradictory studies
have shown that both oral and transdermal oestrogen helps
protect LDL against oxidative damage [7, 8].
Oral oestrogen also improves the postprandial clearance of
potentially atherogenic lipoprotein remnants [9], which again
will help towards the prevention of atheroma. It is not known
whether transdermal oestradiol has this effect. Oral oestrogen
lowers the levels of lipoprotein (a), another lipoprotein risk
marker for CHD, whereas transdermal oestradiol alone has
no effect [3]. 
The addition of androgenic progestogens appears to lower
lipoprotein (a) and this effect is seen with both oral and trans-
dermal HRT. Orally administered oestrogen increases high
density lipoprotein (HDL) cholesterol, and particularly the
HDL2 subfraction which is thought to protect against athero-
sclerosis development primarily through reverse cholesterol
transport. Transdermal oestradiol appears to have a much
lesser effect on increasing HDL cholesterol than oral oestro-
gen [3].
The type and route of administration of oestrogen also
determines its effects on triglycerides. Oestrogens primarily
affect endogenous triglyceride concentrations. Conjugated
equine oestrogens cause an increase in triglycerides [3, 10], due
to the hepatic first-pass effect of this steroid. This may well be
exaggerated with this preparation because the equine compo-
nent appears to have a prolonged cellular retention time. Oral-
ly administered oestradiol has a similar but smaller effect on
raising triglycerides, whereas transdermal oestradiol causes a
reduction in triglycerides [3, 10]. 
Progestogens have differing effects on lipids and lipopro-
teins, depending on their androgenicity and perhaps on their
overall dosage [11]. 
The addition of progestogens to oestrogen therapy has no
adverse effect in terms of LDL reduction, since, although they
increase LDL production, they also increase its clearance.
Androgenic progestogens, such as norgestrel and to a lesser
extent medroxyprogesterone acetate (MPA), reverse the HDL-
raising effect of oestrogen [10] because they increase hepatic
lipase activity. In contrast, certain non-androgenic progesto-
gens, such as dydrogesterone, have little negative impact on
oestrogen-induced increases in HDL and HDL2 [12]. 
Testosterone-derived progestogens, such as levonorgestrel
and norethisterone acetate (NETA), decrease triglyceride lev-
els by reducing secretion of very-low-density lipoprotein
(VLDL). C-21 progestogens do not prevent the increase in
triglycerides induced by oral oestrogens. Thus, combined
oestrogen-progestogen HRT may lead to an increase in HDL
but at the expense of an increase in triglycerides, or lead to a
decrease in triglycerides but at the expense of a decrease, or no
increase, in HDL. 
Which change is more important in terms of CHD benefit
remains unknown but, when all these changes in lipids and
lipoproteins are considered together, the various changes seen
with most HRT combinations are likely to be beneficial over-
all. 
Oestrogen also affects glucose and insulin metabolism.
Oral administration of oestradiol to postmenopausal women
brings changes in glucose and insulin concentrations sugges-
tive of an improvement in insulin resistance, whereas trans-
dermal oestradiol is fairly neutral in its effects [13]. Progesto-
gen addition may modify the effects of oestrogen on glucose
and insulin metabolism, depending on the type of progestogen
used. Testosterone-derived progestogens, such as norgestrel,
may increase insulin resistance [14]. 
NETA given orally may also have a negative effect [13], but
when given transdermally it has little impact [14]. Non-andro-
genic progestogens such as dydrogesterone have little adverse
effect [15], although MPA has unwanted effects.
In certain clinical situations, such as dyslipidaemia or dia-
betes, some HRT regimens will be potentially more beneficial
than others. Thus, oral oestrogens have a superior effect to
transdermal oestradiol in terms of reducing LDL and increas-
ing HDL, whilst transdermal oestradiol is superior in terms of
reducing triglycerides. Oral oestradiol is effective in improving
insulin sensitivity, whereas transdermal has less effect. 
Oral HRT has been shown in two large randomised trials
to reduce the incidence of diabetes in postmenopausal women
[16, 17], whereas there are only data from a small observatio-
nal study to show such an effect with transdermal oestradiol
[18]. 
Oral HRT has the effect of preventing or reversing the
menopausal deposition of central fat [19], whereas transder-
mal HRT does not [20]. Abdominal obesity is associated with
increased circulating levels of leptin and resistin, and
decreased levels of adiponectin and ghrelin. Oral HRT
appears to have little effect on adiponectin and leptin levels
[21, 22], but increases ghrelin levels [23]. The effects of trans-
dermal oestradiol on adipocytokines are unknown.
Oestrogen affects coagulation and fibrinolysis, increasing
both pro-coagulant and fibrinolytic activity. The effects of
oral HRT on haemostasis are somewhat complex [24, 25].
There is a reduction in certain pro-coagulant factors linked
with atheroma development, such as fibrinogen and factor
VII, but also a reduction in anti-coagulant factors such as
antithrombin. Similar changes are seen with transdermal
HRT [6]. 
It is likely that the initiation of oral oestrogen therapy
causes a transient imbalance between coagulation and fibri-
nolysis, thereby causing a short-term increase in thromboem-
bolism risk, which disappears as these processes gradually
readjust and come back into a balance. This would explain the
epidemiological observations of an increase in both arterial
and venous disease risk in the 6-12 months after the initiation
of therapy with a decrease thereafter. However, dosage is also
likely to be important. Oral oestrogen appears to increase
coagulation activation in a dose-dependent manner. A recent
study of low dose oral HRT (oestradiol 1mg and NETA
0.5mg) did not show any adverse changes in coagulation acti-
vation [26]. The non-oral administration of oestrogen may
limit or even avoid this adverse effect [27]. Progestogens are
probably fairly neutral in their effects on haemostasis.
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HRT effects influencing vascular function
The vasodilatory effect of oestrogen may be due in part to
an acute oestrogen receptor-dependent effect on the nitric
oxide synthase (NOS) pathway, which leads to increased levels
of endothelial nitric oxide synthase (eNOS) [28], and
increased production of the potent vasodilator nitric oxide
(NO). NO is involved in regulation of blood pressure, platelet
function, inhibition of vascular smooth-muscle proliferation
and expression of adhesion molecules. Oestradiol increases
NO production, as measured by circulating surrogates. Some
studies have suggested a superior effect of oral over transder-
mal oestradiol in this respect [29], but others have shown the
opposite [30], whilst yet others have shown no difference [31].
When vascular endothelial function has been measured, oral
oestradiol has been shown to have either a greater [32] or sim-
ilar [33] beneficial effect to transdermal oestradiol. Similarly,
both oral and transdermal HRT have been shown to lower the
levels of the cell adhesion molecules E-selectin and vascular
cell adhesion molecule-1 (VCAM-1) in postmenopausal
women [6, 34]. 
Elevated levels of C-reactive protein (CRP) are associated
with increased CHD risk [35], and HRT has an effect on these
levels. Oral HRT has been shown to increase CRP concentra-
tions, whereas transdermal HRT appears to have no effect
[36]. However, the significance of this increase in CRP is
unclear, as it is associated with decreases in other vascular
inflammatory markers [37].
Arterial function may also be affected by oestrogen via
changes in the renin-angiotensin-aldosterone system. Because
of the hepatic first-pass effect, it has been postulated that oral
oestrogen might increase renin substrate activity and aldos-
terone concentrations, thereby adversely affecting blood pres-
sure. Such an effect would not be expected with transdermal
oestradiol. However, oral oestradiol does not increase aldos-
terone levels [38, 39]. Both oral and transdermal HRT have
been shown to reduce circulating angiotensin-1 converting
enzyme (ACE) activity [6, 40], with a greater effect being seen
with oral administration. Small falls in blood pressure are seen
with both oral and transdermal HRT.
Clinical studies of HRT and CHD
Many observational studies have consistently shown that
postmenopausal HRT use is associated with a reduction in
CHD of around 40%. Analyses from the Nurses’ Health Study
have shown that HRT use is effective for both primary and
secondary prevention of CHD [41, 42]. The observational
data relate virtually entirely to oral therapy, with no epidemio-
logical data on transdermal therapy as yet available. 
Randomised trials using clinical endpoints, however, for
CHD have not shown an overall benefit. The HERS trial [43]
of oral HRT (conjugated equine oestrogens 0.625mg and
MPA 2.5mg) for the secondary prevention of CHD showed a
significant trend towards reduction in events, but this was
after an initial increase in events with HRT – the pattern of
early harm followed by later benefit. Exactly the same pattern
was seen in the large primary prevention trial using the same
oral HRT, the Women’s Health Initiative (WHI), again with a
significant trend towards reduction but an early transient
increase in events [44]. 
It has been argued that the early harm was due to an inap-
propriately high starting dose of HRT for the age of the
women participating in the study. This could have led to tran-
sient increases in coagulation activation and adverse vascular
remodelling, thereby causing an early increase in events [45].
Could a different route of administration have avoided this?
The small Papworth HRT atherosclerosis study (PHASE) was
a randomised secondary prevention trial of transdermal
oestradiol with or without the addition of transdermal
NETA, and showed exactly the same pattern of early harm
followed by possible later reduction, and no overall benefit
[46]. However, the dose used, oestradiol 80µg daily, was again
excessive for the age of the patients. Thus, it appears that there
is no difference in CHD outcomes whether HRT is given oral-
ly or transdermally. The more important factor thus appears
to be the dose. The effects of HRT in the younger women (50-
59 years) in the WHI oestrogen-alone trial produced a signifi-
cant reduction in CHD events for the composite endpoint of
myocardial infarction, death and coronary interventions,
probably because for these women the dose of HRT was
appropriate. Older women need lower doses to avoid early
harm, and it is of interest that in two secondary prevention tri-
als where lower starting doses were used, there was no early
increase in coronary events [26, 47]
Compliance
Entering the terms “compliance with hormone therapy,
hormone replacement therapy or oestrogen therapy” into the
database of the US National Library of Medicine and the
National Institutes of Health (containing over 16 million cita-
tions) produces just under 240 references for papers published
between 1991 and 2006. 
The first and most important conclusion is that there is no
really large scale, long-term, randomised, prospective trial
comparing quality of life issues, compliance or continuance
between oral and non-oral regimens.
The largest prospective study with quality of life as a pri-
mary endpoint [48] was of four months duration and involved
74 postmenopausal women randomly assigned to conjugated
equine oestrogens 0.625mg/day or transdermal oestradiol
50mcg with sequential MPA 10mg/day added for 12 days each
cycle. No treatment differences were observed for a variety of
domains measured by a Menopause Specific Quality of Life
questionnaire. A twelve month placebo-controlled study of 60
postmenopausal women with coronary artery disease ran-
domised to transdermal oestradiol 50mcg or conjugated
equine oestrogen 0.625mg/day with both groups again receiv-
ing sequential MPA reported an overall improvement in mood
and cognitive function with both treatments with a similar
increase in quality of life measures (ref. 156). 
The first Kaiser Permanante study report from Northern
California was a retrospective database search for prescription
use in women with an intact uterus in a managed health care
programme [49]. A statistically significant difference in the
continuation rate was observed, with more drop-outs in the
transdermal group applying a 50mcg oestradiol patch com-
pared to the oral group receiving conjugated equine oestro-
gens 0.625mg/day (RR=2.6, 95% confidence interval 1.8 to
3.8). Both groups also took MPA sequentially. 
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A subsequent paper [50] included hysterectomised women
and increased the sample size to 4,458 subjects. This is to date
the largest study comparing oral and non-oral treatments. It
was again observed that women starting treatment with oral
HRT, conjugated equine oestrogens 0.625mg/day, were less
likely to discontinue therapy compared to those starting treat-
ment with transdermal oestradiol 50mcg/day (RR=1.5, 95%
confidence interval 1.3-1.8). This difference was found in both
hysterectomised and non-hysterectomised women.
Perrone et al [51] compared continuous/combined oral and
transdermal treatments with sequential oral and transdermal
therapies using oestradiol 50mcg and conjugated equine
oestrogen 0.625mg/day. MPA was the progestogen which was
added either sequentially or continuously. There were approx-
imately 25 patients in each treatment group and after two
years the drop-out rates were similar between the four groups,
ranging between 31 and 39%. Whilst there were fewer bleeding
problems in the groups receiving continuous/combined treat-
ments in year two, the dropout rate was higher because the
continuous progestogen appeared to cause more breast ten-
derness. There were no differences in continuance between the
oral and transdermal groups. 
The effects of low-dose HRT using conjugated equine
oestrogens 0.3mg/day orally and transdermal oestradiol
25mcg have been reviewed It was concluded that these low
doses are effective in controlling symptoms [52] and reducing
bone loss [53].
Finally, just two studies have compared oral therapy with
a different form of non-oral therapy, namely percutaneous
gel. In a prospective, randomised, open study of 885 women
followed for two years, Serfety et al. [54] reported that a fixed-
dose of oral oestradiol valerate and sequential MPA provided
approximately the same continuance (around 75%) as a vari-
able dose of percutaneous oestradiol gel, (Oestrogel, Labora-
toires Besins-Iscovesco). 
Hirvonen et al. [55] compared oral oestradiol valerate and
sequential MPA with two doses of a different gel, (Sandrena,
Organon Laboratories) and also observed similar continuance
rates between the groups.
The Endometrium
It has been known for many years that the doses of oestra-
diol and oestrone-based preparations needed to control
oestrogen deficiency symptoms effectively cause endometrial
stimulation [56], and will increase the risk of endometrial
hyperplasia and cancer in the long-term unless opposed by a
progestogen at adequate dose and duration [57]. 
For many years it was believed that oestrone was more car-
cinogenic than oestradiol, because firstly postmenopausal
women not receiving HRT who develop endometrial cancer
tend to be overweight/obese and have a higher oestrone than
oestradiol value in plasma (because of the peripheral conver-
sion from androstenedione), and secondly because most of the
early reports linking HRT to an excess risk of endometrial
cancer were associated with conjugated equine oestrogens,
which give rise in plasma principally to oestrone. However,
even in the postmenopausal woman receiving an oestrone
based preparation, the principal oestrogen within the nucleus
of the epithelial endometrial cell is oestradiol [58]. 
The nuclear oestradiol/oestrone ratio is reduced by the
addition of progestogen with consequent lowering of stimula-
tion. This is one of the ways in which progestogens reduce the
risk of hyperplasia and carcinoma [59]. Clinically, comparable
therapeutic oestrogen doses are likely to carry a similar risk of
endometrial cancer irrespective of the route of administra-
tion. Therefore the choice of preparation may depend upon
other factors, such as regularity of bleeding (with sequential
therapy), or lack of bleeding (with continuous/combined
treatments). 
Before commenting on bleeding further, it is stressed that
there are no standard definitions to describe bleeding with
HRT. Some of the definitions established by the World Health
Organization to evaluate bleeding with hormonal contracep-
tion have been applied to HRT but, for the most part, incon-
sistencies in bleeding definitions have made data interpreta-
tion even more difficult. (For a full review of this problem see
Archer and Pickar, 2002) [60]. Again, there are numerous
papers in the literature comprising small patient numbers
and/or short durations of treatment. We have selected three
papers to review. Unfortunately, there are no direct compar-
isons for treatments likely to be considered “first choice” in
2007.
In a prospective, randomised, double-blind, controlled,
trial Johnson et al. [61] compared two oral continuous/com-
bined treatments over 6 months in 438 early postmenopausal
women. One group received oestradiol 1mg/day and NETA
0.5mg/day. The other half took conjugated equine oestrogens
0.625mg/day and MPA 2.5mg/day. The oestradiol/NETA reg-
imen was associated with significantly less bleeding (p<0.005).
No bleeding or spotting was reported in 59% and 68% of
women during cycles 1-3 and 4-6, respectively. Comparable
data for conjugated equine oestrogens and MPA were 60%
and 62%, respectively.
Wyeth has introduced lower dose conjugated equine
oestrogens regimens based on 0.45mg and 0.3mg/day, both
with continuous MPA. Bleeding data for these lower dose reg-
imens are available [62] but comparisons with the data of
Johnson et al. [61] are difficult because of the different expres-
sion of results. “Cumulative no bleeding” was observed in 59%
of women taking conjugated equine oestrogens 0.45mg and
MPA 2.5mg and in 65% taking conjugated equine oestrogens
0.3mg and MPA 1.5mg over 13 cycles of treatment [62].
Ylikorkala and Rozenberg [63] studied patients receiving
fully transdermal therapy based on oestradiol 50µg/day. Allo-
cation to transdermal NETA, either sequentially or continu-
ously, was random. Both sequential and continuous NETA
regimens were given at one of two doses, 170mcg/day or
350mcg/day. Over 90% of subjects bled with sequential thera-
py. The results were expressed for three monthly phases (quar-
ters). The median number of days of bleeding per quarter var-
ied over the study period but no clear pattern of change
emerged. It was about 3 days less with the lower dose of
NETA, (12-17 days) compared to the higher dose (16-19
days). The continuous data were expressed on an intention-to-
treat analysis of subjects starting treatment in each quarter.
This is again different from the other papers considered here.
Amenorrhea was reported by around 35% of women during
the first quarter, by around 47% during the fourth quarter
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(end of year one), and by approximately 57% by the eighth
quarter at the end of two years. Our interpretation is that
transdermal continuous/combined regimens are associated
with more bleeding than the oral regimens.
Breast Status 
Incident Breast Cancer
Because of the prevalence, large scale studies (thousands
of women) are required to determine whether oestrogens
influence incident breast cancer risk. Randomised controlled
trials have been performed with oral therapy but no compara-
ble data are available for transdermal treatment. However, it
would be most unwise to assume that non-oral routes will not
impact on breast cancer risk. “Absence of evidence” must not
be confused with “evidence of absence”.
The Womens Health Initiative reported that a continuous
regimen of conjugated equine estrogens, 0.625mg/day and
MPA 2.5mg/day, increased the risk of incident breast cancer
after a mean of 5.2 years. There were 8,506 active users and
8,102 women in the placebo group. The hazard ratio (HR) was
1.26 (nominal 95% confidence interval 1.00-1.59) Thus, the
absolute risk was increased from 30 per 10,000 person years to
38 per 10,000 person years. (Writing Group for the Womens
Health Initiative Study, 2002) [64]. There was no increase in
risk in women traditionally considered at high risk eg those
with a family history.  At the time of publication there had
been 5 deaths due to breast cancer, 3 in the active group and 2
in the placebo users.
After a mean of 7.1 years of treatment with conjugated
equine estrogens alone, 0.625mg/ day, in hysterectomised
women the HR for incident breast cancer was reduced at
0.8.(95% confidence interval 0.62-1.04). This reduction was
not significant (P=0.9). There were 5,310 active users and
5,429 placebo-users (Stefanick et al., 2006). The precise reason
for the differences between the results is not known but one
explanation would be that the progestogen, MPA, is responsi-
ble for the increase in risk observed with combined therapy.
Whether other progestogens have similar effects is not known.
The Million Women Study, an observational study, reported
similar increases in risk of incident breast cancer with all com-
monly prescribed progestogens eg NETA, norgestrel, and
MPA [65].
This study, however, has various methodological deficien-
cies and has been critiqued [66]. These include relying on
patient recall for details of treatment, and only recording cur-
rent treatment. No details of past use were collected. 
We consider this a major error when it is known that 45%
of women will have changed  their form of HRT at least once
during the first 2-3 years of therapy. We consider the data
from the Million Women Study unreliable.
Breast Density
This is an area of much confusion. Breast density is
dependent upon many factors including age, body mass index,
nulliparity and age at first pregnancy. Additionally, a recent
study of twins reported that the heritable percentage of the
density-risk relationship was approximately 65%, ie about
two-thirds of the risk was genetically conferred [67]. 
In postmenopausal women not using HRT it is well recog-
nised that the more dense the breast the greater the risk of
breast cancer. With oral HRT it is widely reported that the
greatest increases in density are observed with continuous
combined treatments, then sequential therapies and the small-
est increases occur with oestrogen-alone. These data have been
extensively reviewed [68, 69]. 
However, what is not clear is whether those women show-
ing the greatest changes in breast density with HRT are those
who go onto develop the disease.
The changes in density with non-oral treatments are much
less well studied: indeed, we can find only two reports in the
literature with transdermal therapy. Lundstrom et al. (2001)
[70] reported that in 55 women receiving transdermal oestra-
diol 50mcg/day an increase in mammographic density was
seen in 2%. With oral oestriol 2mg/day an increase was seen in
6%. Finally, Harvey et al. (2005) [38, 39] compared fully trans-
dermal therapy based upon 50mcg/day of oestradiol with a
continuous combined oral HRT of oestradiol 2mg/day and
NETA 1mg/day. Four percent of women using the transder-
mal treatment had a significant increase in mammographic
breast density compared to 16% with oral HRT. The authors
concluded that transdermal HRT has a lower incidence of
increased mammographic density. Our concern is that this
study did not compare oestrogen preparations of equal poten-
cy and we would like to see the study repeated using oestradi-
ol 50mcg/day compared with oral oestradiol 1mg/day, and
preferably without a progestogen because of possible con-
founding by this hormone. 
Most importantly, though, is the need to show that
changes in mammographic breast density with HRT accurate-
ly predict those women at an increase in cancer risk. Whilst we
can follow the pathway of increased breast density potentially
signifying harm with oestrogen/progestogen HRT which
increases incident breast cancer, we cannot follow this logic
with oestrogen alone. This treatment increases density yet the
controlled data report a 20% reduction in cancer risk!
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Oral versus non-oral hormone replacement therapy: How important is the route of administration?
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The evaluation of selected indices of
apoptosis in placentas from pregnancies
complicated by fetal growth restriction 
Zachowanie sie wybranych parametrów oceny apoptozy 
w ∏o˝yskach pochodzàcych z cià˝ powik∏anych hipotrofià 
wewnàtrzmacicznà.
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Abstract
Background: Fetal growth restriction is related to a high rate of prematurity and mortality. In cases of unknown
origin utero-placental circulation changes are the main factor which is due to the changes in blood vessels. The
understanding of the mechanism may help in further prevention of FGR.
Material and methods: The expression of bcl-2 and bax in normal pregnancies and complicated by FGR were com-
pared. The study was conducted in 2005-2006 at The Medical University of Lodz – HRP Unit and The Kopernik
Hospital – Lodz.
Bcl-2 and bax were estimated using an immunohistochemical method. Bcl-2 was estimated in trophoblast, bax in
decidua and trophoblast.
Results: In a study group the mean value of bcl-2 in trophoblast was 37,04±10,51, in a control group the mean
value was 65,74±6,97. The estimation of bax was done in trophoblast and decidua separately. In the group of FGR
mean value of bax expression in trophoblast was 45,35±10,5. In decidua the mean bax expression value was
24,11±7,3. In controls in trophoblast the  mean value was 12,53±7,54, in decidua the mean expression of bax was
6,63±2,24.
Conclusion: 1. Apoptosis in trophoblast is lower in normal pregnancy than in FGR. 
2. Increased expression of pro-apoptotic proteins in placenta might be one of the reason for FGR development.
Key words: apoptosis / bax / bcl-2 / fetal growth retardation – physiopathology / 
/ pregnancy complications – pathology / pregnancy complications 
– physiopathology / placenta – pathology / trophoblasts – pathology /
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